Abstract 3755: Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214Saul Kivimäe, Jonathan Zalevsky, Janet Cetz et al.|Cancer Research|2018Cited by 19
Combining complementary mechanisms of immune activation: NKTR-214, a biased IL-2 pathway agonist and immune checkpoint antagonistsDeborah H. Charych, Jonathan Zalevsky, Steve Doberstein et al.|Annals of Oncology|2016Cited by 0
Abstract 1617: Mechanistic modeling of a new kinetically-controlled CD122 agonist for cancer immunotherapy: NKTR-214 pharmacokinetics, pharmacodynamics, and receptor pharmacologySamira Khalili, Ute Hoch, Aleksandrs Odinecs et al.|Cancer Research|2017Cited by 0